hepat
c
viru
hcv
infect
treatment
dramat
improv
thank
introduct
directact
antivir
agent
daa
antivir
significantli
increas
respons
rate
greatli
reduc
treatment
durat
current
avail
daa
classifi
four
categori
given
molecular
target
hcv
replic
cycl
proteas
inhibitor
pi
bind
activ
site
proteas
inhibitor
interact
domain
dimer
although
exact
mechan
inhibit
remain
fulli
elucid
nucleo
ide
analog
polymeras
inhibitor
incorpor
nascent
rna
chain
result
chain
termin
compromis
bind
incom
nucleotid
nonnucleosid
polymeras
inhibitor
interact
either
thumb
thumb
palm
palm
domain
inhibit
polymeras
activ
alloster
mechan
howev
extrem
mutat
high
replic
rate
hcv
togeth
immun
system
pressur
lead
remark
genet
variabl
compromis
high
respons
rate
daa
due
preexist
resistanceassoci
substitut
rass
drug
class
daa
character
specif
resist
profil
likelihood
daa
select
allow
outgrowth
viral
popul
carri
rass
depend
daa
genet
barrier
resist
number
type
mutat
need
gener
amino
acid
substitut
confer
resist
viral
fit
replic
capac
resist
variant
viral
genotyp
subtyp
preval
rass
patient
broadli
report
worldwid
howev
apart
brazil
argentina
issu
fulli
address
south
american
countri
yet
lack
inform
relat
preexist
baselin
rass
ad
high
cost
new
drug
major
limit
factor
broad
implement
new
therapi
uruguay
well
latin
american
countri
low
lowermiddl
incom
studi
explor
presenc
resist
variant
inhibitor
daa
treatment
cohort
uruguayan
patient
chronic
infect
hepat
c
aim
contribut
knowledg
circul
hcv
resist
variant
south
american
region
serum
sampl
obtain
patient
serolog
marker
hcv
recruit
gastroenterolog
clinic
hospit
de
montevideo
uruguay
hcv
infect
confirm
abbott
realtim
hcv
abbott
molecular
inc
de
plain
usa
patient
select
studi
chronic
infect
hcv
genotyp
daa
time
blood
extract
written
inform
consent
obtain
patient
studi
perform
accord
world
medic
associ
declar
helsinki
approv
appropri
institut
board
hospit
de
ethic
committe
viral
rna
extract
serum
use
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
accord
manufactur
protocol
viral
rna
heat
min
use
templat
revers
transcript
reaction
revers
transcript
reaction
mixtur
contain
rna
templat
random
hexam
invitrogen
life
technolog
carlsbad
ca
usa
dntp
mix
mm
firststrand
buffer
dtt
superscript
ii
revers
transcriptas
invitrogen
life
technolog
carlsbad
ca
usa
rnaseout
invitrogen
life
technolog
carlsbad
ca
usa
revers
transcript
perform
min
revers
transcriptas
enzym
inactiv
min
pcr
amplif
genom
region
perform
use
primer
condit
previous
describ
amplicon
purifi
use
illustra
gfx
pcr
dna
gel
band
purif
kit
ge
healthcar
life
scienc
buckinghamshir
uk
accord
manufactur
protocol
purifi
product
sequenc
use
set
primer
use
pcr
amplif
bidirect
sanger
sequenc
perform
macrogen
korea
http
wwwmacrogencom
hcv
consensu
sequenc
obtain
uruguayan
patient
align
sequenc
hcv
repres
genotyp
main
subtyp
isol
differ
geograph
region
world
sequenc
obtain
lo
alamo
hcv
sequenc
databas
niaid
viru
pathogen
databas
analysi
resourc
vipr
strain
includ
studi
see
supplementari
materi
tabl
sequenc
align
use
clustal
w
softwar
align
best
evolutionari
model
describ
sequenc
data
assess
use
modelgener
program
use
gtr
g
model
gener
time
revers
gamma
invari
site
maximum
likelihood
phylogenet
tree
construct
use
mega
softwar
nucleotid
posit
rel
hcv
refer
strain
includ
phylogenet
analysi
wherea
nucleotid
correspond
okamoto
region
posit
rel
strain
includ
measur
robust
node
employ
bootstrap
method
pseudorepl
uruguayan
sequenc
n
second
align
maximum
likelihood
phylogenet
tree
gener
order
analyz
hcv
evolutionari
relationship
uruguayan
brazilian
worldwid
strain
nonuruguayan
strain
includ
analysi
see
supplementari
materi
tabl
order
properli
identifi
substitut
chang
region
hcv
strain
circul
uruguayan
patient
gener
world
consensu
sequenc
subtyp
use
wide
rang
sequenc
hcv
strain
isol
worldwid
purpos
gene
sequenc
correspond
subtyp
n
n
retriev
lo
alamo
hcv
sequenc
databas
niaid
vipr
likewis
dataset
sequenc
gener
subtyp
respect
use
seqman
program
implement
dnastar
packag
dnastar
madison
usa
world
consensu
nucleotid
sequenc
gener
gene
subtyp
uruguayan
sequenc
subsequ
align
correspond
refer
sequenc
silico
translat
amino
acid
sequenc
obtain
compar
order
explor
presenc
rass
well
presenc
polymorph
ra
posit
rap
uruguayan
hcv
strain
rap
defin
chang
refer
sequenc
specif
genotyp
posit
associ
resist
studi
genet
variabl
region
hcv
strain
circul
uruguayan
patient
sequenc
region
access
number
align
correspond
sequenc
hcv
strain
isol
elsewher
repres
genotyp
main
subtyp
strain
includ
analys
see
supplementari
materi
tabl
therefor
maximum
likelihood
phylogenet
tree
construct
result
studi
shown
figur
figur
figur
b
strain
phylogeni
assign
accord
genotyp
cluster
support
high
bootstrap
valu
analyz
region
strain
isol
uruguayan
patient
n
assign
genotyp
correspond
subtyp
subtyp
result
figur
figur
b
phylogenet
analys
concord
genom
region
sequenc
suggest
recombin
event
region
analyz
evolutionari
relationship
uruguayan
strain
circul
brazil
elsewher
second
maximum
likelihood
phylogenet
tree
sequenc
partial
region
built
figur
previous
describ
two
distinct
clade
clade
observ
brazilian
sequenc
cluster
larg
group
relat
sequenc
insid
clade
wherea
uruguayan
strain
red
cluster
particular
clade
rather
group
dispersedli
within
major
world
clade
purpos
studi
amino
acid
aa
substitut
along
protein
uruguayan
hcv
aa
sequenc
align
world
consensu
sequenc
residu
rel
protein
sequenc
aa
substitut
posit
previous
found
potenti
associ
resist
inhibitor
well
polymorph
ra
posit
identifi
result
summar
tabl
rass
inhibitor
identifi
strain
fulli
sequenc
sampl
rap
found
strain
subtyp
exhibit
substitut
substitut
although
substitut
report
resist
chang
posit
previous
describ
rass
subtyp
name
final
substitut
found
one
subtyp
strain
chang
consid
secondari
substitut
although
confer
resist
combin
known
ra
fact
confer
higher
level
resist
one
achiev
ra
alon
addit
sever
polymorph
previous
report
associ
resist
phenotyp
also
detect
see
supplementari
materi
tabl
order
studi
substitut
along
protein
uruguayan
hcv
aa
sequenc
align
world
consensu
sequenc
almost
fulllength
aa
sequenc
obtain
analyz
strain
sequenc
span
residu
wherea
remain
span
residu
protein
issu
limit
studi
sinc
mani
describ
rass
observ
residu
importantli
rass
inhibitor
tabl
observ
strain
sequenc
sampl
found
two
isol
found
one
strain
abl
obtain
longer
sequenc
rass
subtyp
subtyp
observ
final
found
two
rap
subtyp
strain
subtyp
strain
although
associ
resist
beclabuvir
bcv
patient
infect
hcv
subtyp
resist
phenotyp
proven
strain
subtyp
posit
substitut
report
resist
case
differ
polymorph
previous
associ
resist
phenotyp
also
detect
see
supplementari
materi
tabl
advent
daa
therapi
constitut
one
major
breakthrough
hcv
infect
patient
manag
howev
new
treatment
option
far
univers
avail
particular
hcv
infect
patient
reli
latin
american
public
healthcar
system
main
limit
factor
worldwid
access
daa
region
concern
high
cost
inadequ
manag
public
healthcar
system
limit
access
lowincom
uninsur
popul
healthcar
provid
lack
accur
epidemiolog
inform
uruguay
therapi
becam
recent
avail
although
approv
use
public
health
author
viekira
pak
sofosbuvirledipasvir
therapi
current
financi
cover
except
specif
case
despit
high
rate
viral
respons
achiev
daabas
treatment
still
patient
fail
elimin
infect
case
baselin
emerg
resist
variant
turn
key
factor
contribut
treatment
failur
unfortun
current
unabl
properli
assess
number
hcv
infect
peopl
uruguay
even
figur
frequenc
type
rass
circul
fact
could
compromis
effect
new
therapi
countri
previous
report
natur
occur
substitut
confer
resist
inhibitor
exist
signific
proport
uruguayan
patient
infect
hcv
genotyp
show
frequenc
seem
higher
south
american
countri
brazil
argentina
present
studi
describ
preval
baselin
rass
hcv
genotyp
infect
patient
uruguayan
cohort
presenc
substitut
confer
resist
inhibitor
wide
report
relaps
patient
europ
usa
asia
howev
sequenc
south
america
poorli
analyz
yet
recent
studi
reveal
mean
preval
genotyp
baselin
rass
differ
inhibitor
rang
use
popul
sequenc
deep
sequenc
importantli
preval
type
baselin
rass
vari
slightli
geograph
region
instanc
found
genotyp
infect
patient
europ
oceania
strikingli
patient
usa
reason
believ
need
contribut
data
region
still
enough
inform
apart
brazil
result
studi
indic
presenc
daa
rass
hcv
strain
patient
enrol
studi
baselin
rass
detect
posit
see
tabl
substitut
confer
resist
daclatasvir
dcv
ledipasvir
ldv
elbasvir
ebv
subtyp
wherea
substitut
dcv
subtyp
ldv
subtyp
ebv
subtyp
given
clinic
relev
rass
detect
baselin
may
influenc
choic
firstlin
treatment
regimen
substitut
found
two
patient
consid
resistanceassoci
polymorph
rap
rass
character
posit
substitut
found
baselin
rap
relaps
ldv
harvoni
prescript
http
wwwgileadcommediafilespdfsmedicinesliverdiseaseharvoniharvonipipdf
laen
howev
sometim
regard
ra
despit
confer
fold
chang
resist
vitro
studi
use
replicon
system
find
substitut
previous
report
brazil
worldwid
amino
acid
substitut
found
one
uruguayan
patient
although
chang
confer
resist
combin
gener
high
resist
level
dcv
presenc
baselin
rass
impact
treatment
outcom
patient
group
affect
svr
rate
detect
preexist
rass
may
play
relev
role
choic
firstlin
treatment
regimen
simplificationshorten
recommend
regimen
order
bring
svr
rate
close
highest
achiev
particular
countri
uruguay
two
differ
daacontain
treatment
regimen
approv
use
regard
gene
global
analysi
except
south
america
reveal
daa
resist
substitut
infrequ
studi
show
presenc
inhibitor
rass
analyz
hcv
infect
uruguayan
patient
treatment
substitut
found
work
associ
subtyp
resist
bcv
dasabuvir
dsv
respect
associ
resist
dsv
genotyp
substitut
observ
two
uruguayan
patient
report
previous
patient
fail
clear
infect
treatment
obvptvr
dsv
rbv
case
appear
combin
trial
coral
icohort
http
wwwhcvtrialscomshowstudyasp
rap
posit
two
subtyp
isol
one
subtyp
isol
also
found
although
associ
resist
bcv
patient
subtyp
phenotyp
proven
strain
subtyp
posit
substitut
report
resist
subtyp
subtyp
confer
resist
dsv
contrast
result
nobl
cowork
report
presenc
brazilian
isol
yet
none
mutat
found
studi
probabl
due
divers
found
uruguayan
brazilian
strain
figur
nevertheless
substitut
found
brazil
argentina
uruguay
ra
detect
neither
brazilian
report
current
work
uruguay
find
confirm
complement
previou
studi
evidenc
low
preval
substitut
vivo
probabl
due
low
replic
fit
despit
result
worth
mention
presenc
baselin
rass
confer
resist
nucleotid
nonnucleosid
inhibitor
shown
impact
virolog
respons
thu
far
result
show
divers
baselin
polymorph
found
differ
latin
american
countri
evolutionari
relationship
uruguayan
isol
figur
fact
could
link
isol
geograph
region
viral
intrins
characterist
also
genet
background
host
worth
mention
live
vast
contin
inhabit
popul
differ
genotyp
characterist
might
depend
situat
requir
differ
approach
treatment
inde
recent
found
allel
genotyp
frequenc
locu
uruguayan
individu
close
resembl
admix
popul
rather
uniformli
europeandescend
one
altogeth
believ
could
import
carri
studi
throughout
south
american
region
order
establish
preval
rass
differ
countri
fact
aid
understand
everi
treatment
regimen
might
adequ
everi
patient
countri
data
present
might
guid
physician
make
therapeut
decis
also
public
health
author
approv
divers
treatment
combin
treatment
formul
would
cover
circul
strain
region
region
extrem
divers
genet
background
popul
knowledg
present
studi
reveal
first
time
presenc
rass
region
hcv
genotyp
uruguayan
strain
patient
previous
treat
daa
one
south
american
countri
report
matter
current
unclear
preexist
viral
variant
reduc
suscept
daa
clinic
relev
predict
virolog
treatment
failur
howev
individu
daa
therapi
base
baselin
resist
analysi
may
benefici
optim
treatment
efficaci
patient
hcv
genotyp
infect
risk
factor
treatment
failur
therefor
potenti
role
baselin
resist
test
remain
area
critic
research
clinic
question
